Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

When Serum C-Peptide Measurement Drives Adequate Diabetes Mellitus Diagnosis and Therapy: A Case Report

Author(s): Giuseppe Lisco, Sara Volpe, Domenico Triggiani, Vincenzo Triggiani and Giuseppina Piazzolla*

Volume 23, Issue 7, 2023

Published on: 15 February, 2023

Page: [1005 - 1009] Pages: 5

DOI: 10.2174/1871530323666230130151808

Price: $65

Abstract

Background: Therapeutic targets in type 2 diabetes mellitus (T2D) are oriented towards nephron- and cardio-protection and the prescription of antihyperglycemic agents with proven renal and cardiovascular benefits are increasing over time. Failure to promptly diagnose insulinopenic diabetes may adversely affect the adequacy of treatment and have harmful consequences, including severe hyperglycemia and diabetic ketoacidosis.

Case Presentation: Herein we present the case of a 57-year-old woman referred to our clinic due to poor glycemic control (HbA1c 80 mmol/mol, therapeutic target <53 mmol/mol), class III obesity (BMI 41 kg/m2; normal value <25 kg/m2), and high cardiovascular risk misdiagnosed with T2D several years before. C-peptide measurement (0.3 ng/dL; reference range 1.1 – 4.4 ng/mL) confirmed the diagnosis of an insulinopenic form of diabetes, and the islet autoimmunity was consequently measured (GADA 2,000 UA/mL, reference range <5 UA/mL; IA2 17.1 UA/mL, reference range <7.5 UA/mL) and defined the diagnosis of an autoimmune form of diabetes.

Discussion: Deprescribing insulin therapy in T2D patients in favor of other antihyperglycemic medications has become a growing therapeutic opportunity to provide adequate glucose control, promote weight loss, improve insulin sensitivity, and ameliorate cardiovascular and renal outcomes. However, a blunted insulin reserve poses significant restriction on the prescription of non-insulin agents (e.g., diabetic ketoacidosis due to gliflozins). According to our experience, the routine testing of insulin reserve provides detailed information on diabetes pathophysiology with positive implications for the appropriateness of pharmacological prescriptions.

Conclusion: As part of our routine evaluation of diabetic patients, C-peptide measurement is a valuable and inexpensive tool to reclassify diabetes types and provide more appropriate disease management.

Keywords: c-peptide, latent autoimmune diabetes of adult, islet autoimmunity, type 2 diabetes, insulin therapy, insulin.

Next »
Graphical Abstract

[1]
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[2]
Katsarou, A.; Gudbjörnsdottir, S.; Rawshani, A.; Dabelea, D.; Bonifacio, E.; Anderson, B.J.; Jacobsen, L.M.; Schatz, D.A.; Lernmark, Å. Type 1 diabetes mellitus. Nat. Rev. Dis. Primers, 2017, 3(1), 17016.
[http://dx.doi.org/10.1038/nrdp.2017.16] [PMID: 28358037]
[3]
Rajkumar, V.; Levine, S.N. Latent Autoimmune Diabetes; StatPearls Publishing: Treasure Island, FL, 2022.
[4]
Buzzetti, R.; Tuomi, T.; Mauricio, D.; Pietropaolo, M.; Zhou, Z.; Pozzilli, P.; Leslie, R.D. Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes, 2020, 69(10), 2037-2047.
[http://dx.doi.org/10.2337/dbi20-0017] [PMID: 32847960]
[5]
Rowlands, J.; Heng, J.; Newsholme, P.; Carlessi, R. Pleiotropic effects of glp-1 and analogs on cell signaling, metabolism, and function. Front. Endocrinol., 2018, 9, 672.
[http://dx.doi.org/10.3389/fendo.2018.00672] [PMID: 30532733]
[6]
Brahmkshatriya, P.P.; Mehta, A.A.; Saboo, B.D.; Goyal, R.K. Characteristics and prevalence of latent autoimmune diabetes in adults (LADA). ISRN Pharmacol., 2012, 2012, 1-8.
[http://dx.doi.org/10.5402/2012/580202] [PMID: 22577577]
[7]
Hjort, R.; Ahlqvist, E.; Carlsson, P.O.; Grill, V.; Groop, L.; Martinell, M.; Rasouli, B.; Rosengren, A.; Tuomi, T.; Åsvold, B.O.; Carlsson, S. Overweight, obesity and the risk of LADA: results from a Swedish case–control study and the Norwegian HUNT Study. Diabetologia, 2018, 61(6), 1333-1343.
[http://dx.doi.org/10.1007/s00125-018-4596-0] [PMID: 29589073]
[8]
Becht, F.; Walther, K.; Martin, E.; Nauck, M. Fasting C-peptide and related parameters characterizing insulin secretory capacity for correctly classifing Diabetes Type and for predicting insulin requirement in patients with Type 2 Diabetes. Exp. Clin. Endocrinol. Diabetes, 2016, 124(3), 148-156.
[http://dx.doi.org/10.1055/s-0035-1565177] [PMID: 26824281]
[9]
Leighton, E.; Sainsbury, C.A.R.; Jones, G.C. A practical review of C-Peptide testing in diabetes. Diabetes Ther., 2017, 8(3), 475-487.
[http://dx.doi.org/10.1007/s13300-017-0265-4] [PMID: 28484968]
[10]
Hellström, W.; Hansen-Pupp, I.; Hellgren, G.; Engström, E.; Stigson, L.; Sävman, K.; Ley, D.; Löfqvist, C. C-peptide suppression during insulin infusion in the extremely preterm infant is associated with insulin sensitivity. J. Clin. Endocrinol. Metab., 2019, 104(9), 3902-3910.
[http://dx.doi.org/10.1210/jc.2018-02681]
[11]
Maddaloni, E. Bolli, G.B.; Frier, B.M.; Little, R.R.; Leslie, R.D.; Pozzilli, P.; Buzzetti, R. C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. Diabetes Obes. Metab., 2022, 24(10), 1912-1926.
[http://dx.doi.org/10.1111/dom.14785] [PMID: 35676794]
[12]
Albareda, M.; Rigla, M.; Rodríguez-Espinosa, J.; Caballero, A.; Chico, A.; Cabezas, R.; Carreras, G.; Pérez, A. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res. Clin. Pract., 2005, 68(3), 202-206.
[http://dx.doi.org/10.1016/j.diabres.2004.10.005] [PMID: 15936461]
[13]
Jones, A.G.; Hattersley, A.T. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet. Med., 2013, 30(7), 803-817.
[http://dx.doi.org/10.1111/dme.12159] [PMID: 23413806]
[14]
Hædersdal, S.; Lund, A.; Knop, F.K.; Vilsbøll, T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin. Proc., 2018, 93(2), 217-239.
[http://dx.doi.org/10.1016/j.mayocp.2017.12.003] [PMID: 29307553]
[15]
Sanches, J.M.; Zhao, L.N.; Salehi, A.; Wollheim, C.B.; Kaldis, P. Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. FEBS J., 2023, 290(3), 620-648.
[http://dx.doi.org/10.1111/febs.16306] [PMID: 34847289]
[16]
Nauck, M.A.; Quast, D.R. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front. Endocrinol., 2021, 12, 645566.
[http://dx.doi.org/10.3389/fendo.2021.645566] [PMID: 33854484]
[17]
Volpe, S.; Tortorella, C.; Solfrizzi, V.; Piazzolla, G. When inappropriate use of insulin is dangerous: The utility of C-Peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes Metab. Syndr. Obes., 2021, 14, 3517-3521.
[http://dx.doi.org/10.2147/DMSO.S321340] [PMID: 34385826]
[18]
Piazzolla, G.; Vozza, A.; Volpe, S.; Bergamasco, A.; Triggiani, V.; Lisco, G.; Falconieri, M.; Tortorella, C.; Solfrizzi, V.; Sabbà, C. Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience. Open Med., 2022, 17(1), 1203-1215.
[http://dx.doi.org/10.1515/med-2022-0504] [PMID: 35859794]
[19]
Bermúdez, V.; Aparicio, D.; Colmenares, C.; Peñaranda, L.; Luti, Y.; Gotera, D.; Rojas, J.; Cabrera, M.; Reyna, N.; Velasco, M.; Israili, Z.H. Latent autoimmune diabetes in adults: A case report. Am. J. Ther., 2010, 17(3), 284-287.
[http://dx.doi.org/10.1097/MJT.0b013e3181c121ac] [PMID: 20224323]
[20]
Costa, J.R.; Mestre, A.; Miranda, M.S.; Ferreira, F.H.; Abuowda, Y. A case of late diagnosis of latent autoimmune diabetes in adults. Cureus, 2022, 14(2), e21826.
[http://dx.doi.org/10.7759/cureus.21826] [PMID: 35282513]
[21]
Bozkuş; Y. A case report of latent autoimmune diabetes arising after isotretinoin treatment: Real association or coincidence? a hypothesis on pathophysiology. Endocr. Metab. Immune Disord. Drug Targets, 2021, 21(12), 2307-2310.
[http://dx.doi.org/10.2174/1871530321666210713123256] [PMID: 34259153]
[22]
Kang, C.Y.; Khamooshi, P.; Reyes Pinzon, V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus, 2022, 14(4), e24016.
[http://dx.doi.org/10.7759/cureus.24016] [PMID: 35573514]
[23]
Foteinopoulou, E.; Clarke, C.A.L.; Pattenden, R.J.; Ritchie, S.A.; McMurray, E.M.; Reynolds, R.M.; Arunagirinathan, G.; Gibb, F.W.; McKnight, J.A.; Strachan, M.W.J. Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of type 1 diabetes. Diabet. Med., 2021, 38(7), e14449.
[http://dx.doi.org/10.1111/dme.14449] [PMID: 33131101]

Rights & Permissions Print Cite
Article Metrics
28
2
© 2024 Bentham Science Publishers | Privacy Policy